Snake venom proteome of Protobothrops mucrosquamatus in Taiwan: Delaying venom-induced lethality in a rodent model by inhibition of phospholipase A2 activity with varespladib
Chien-Chun Liu,Cho-Ju Wu,Yung-Chin Hsiao,Ya-Han Yang,Kuei-Lin Liu,Guo-Jen Huang,Cheng-Hsien Hsieh,Chun-Kuei Chen,Geng-Wang Liaw
DOI: https://doi.org/10.1016/j.jprot.2020.104084
IF: 3.855
2021-03-01
Journal of Proteomics
Abstract:<p><em>Protobothrops mucrosquamatus</em>, also known as the brown spotted pit viper or Taiwanese habu, is a medically significant venomous snake in Taiwan, especially in the northern area. To more fully understand the proteome profile of <em>P. mucrosquamatus</em>, we characterized its venom composition using a bottom-up proteomic approach. Whole venom components were fractionated by RP-HPLC and then analyzed by SDS-PAGE. Each protein band in gels was excised and subjected to protein identification by LC-MS/MS. A subsequent proteomic analysis revealed the presence of 61 distinct proteins belonging to 19 families in <em>P. mucrosquamatus</em> venom. Snake venom metalloproteinase (SVMP; 29.4%), C-type lectin (CLEC; 21.1%), snake venom serine protease (SVSP; 17.6%) and phospholipase A<sub>2</sub> (PLA<sub>2</sub>; 15.9%) were the most abundant protein families, whereas several low-abundance proteins, categorized into eight protein families, were demonstrated in <em>P. mucrosquamatus</em> venom for the first time. Because PLA<sub>2</sub> is known to make a major contribution to venom lethality, we evaluated whether the known PLA<sub>2</sub> inhibitor, varespladib, was capable of preventing the toxic effects of <em>P. mucrosquamatus</em> venom. This small-molecule drug demonstrated the ability to inhibit PLA<sub>2</sub> activity <em>in vitro</em> (IC<sub>50</sub> = 101.3 nM) It also blunted lethality <em>in vivo</em>, prolonging survival following venom injection in a mouse model, but it showed limited potency against venom-induced local hemorrhage in this model. Our findings provide essential biological and pathophysiological insights into the composition of <em>P. mucrosquamatus</em> venom and suggest PLA<sub>2</sub> inhibition as an adjunctive or alternative therapeutic strategy in the clinical management of <em>P. mucrosquamatus</em> envenoming in emergency medicine.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Significance</h3><p><em>P. mucrosquamatus</em> envenomation is a significant medical concern in Taiwan, especially in the northern region. Although antivenom is commonly used for rescuing <em>P. mucrosquamatus</em> envenoming, severe clinical events still occur, with more than 20% of cases requiring surgical intervention. Small-molecule therapy offers several advantages as a potential adjunctive, or even alternative, to antivenom treatment, such as heat stability, low antigenicity and ease of administration, among others. A deeper understanding of the venom proteome of <em>P. mucrosquamatus</em> would aid in the discovery of small-molecule drugs that could be repurposed to target specific venom proteins. Here, we applied a bottom-up proteomic approach to characterize the protein profile of <em>P. mucrosquamatus</em> venom. Varespladib, a small-molecule drug used to treat inflammatory disease, was repurposed to inhibit the toxicity of <em>P. mucrosquamatus</em> venom, and was shown to reduce the lethal effects of <em>P. mucrosquamatus</em> envenomation in a rodent model. Varespladib might be used as a first-aid therapeutic against <em>P. mucrosquamatus</em> envenoming in the pre-referral period and/or as an adjunctive agent administered together with anti-<em>P. mucrosquamatus</em> antivenom.</p>
biochemical research methods